Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which Co. is able to genetically select patients most likely to benefit. Co.'s primary product candidate, milademetan, is a small molecule, oral inhibitor of mouse double minute 2, which may be oncogenic in various cancers. In addition to milademetan, Co. is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. We show 9 historical shares outstanding datapoints in our RAIN shares outstanding history coverage, used to compute RAIN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RAIN market cap history over the course of time is important for investors
interested in comparing RAIN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RAIN versus a peer is one thing; comparing
RAIN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RAIN can fluctuate over the course of history.
With this page we aim to empower investors researching RAIN by allowing them to research the RAIN market cap history. |
Free RAIN Email Alerts:
Video: The Importance of Market Cap
